卡托普利对大鼠肝纤维化治疗作用的实验研究  

Study of Captopril therapeutic effect on rat hepatic fibrosis

作　　者：鲁福德[1] 李芳健[2] 严永杰[1] 林春英[1] 

机构地区：[1]广州医学院从化学院,广东广州510925 [2]广州医学院公共卫生与全科医学学院,广东广州510182

出　　处：《中国现代医学杂志》2011年第14期1580-1582,共3页China Journal of Modern Medicine

基　　金：2009年广东省中医药管理局课题(No:2009249)

摘　　要：目的探讨卡托普利对大鼠肝纤维化的治疗作用及其机制。方法采用四氯化碳(CCl4)制造大鼠肝纤维化模型,设正常组、模型组、卡托普利低剂量组和卡托普利高剂量组,采用放射免疫法测定血液和肝匀浆中肾素活性、血管紧张素和醛固酮;采用紫外分光光度法测定血管紧张素转换酶活性;图像分析法判定肝纤维化程度。结果卡托普利能降低肝内肾素-血管紧张素-醛固酮系统(RAAS)活性(P<0.01),减轻肝纤维化(P<0.01),两剂量之间差异无显著性。结论卡托普利具有抗肝纤维化作用;其机制可能是抑制肝内RAAS激活。【Objective】 To investigate the effects of Captopril on rat hepatic fibrosis and explore the underlying mechanism.【Methods】 Forty healthy SD rats were randomly divided into four groups： normal control group,model group,Captopril low dosage group,Captopril high dosage group.Liver and plasma renin activity,angiotensin I 11,and aldosterone were detected by radio-immunoassay.Angiotensin converting enzyme activity was detected by ultra-violet spectrophotography.The area of collagen was examined by the image analysis system.【Results】 Captopril could inhibit the liver rennin-angiotensin-aldosterone system（P 0.01）,and ameliorate liver fibrosis（P 0.01）.There was no difference between two dosage groups.【Conclusion】 Captopril could attenuate rat liver fibrogenesis by inhibiting the activity of the liver rennin-angiotensin-aldosterone system.

关 键 词：卡托普利 肝纤维化 RAAS 

分 类 号：R575[医药卫生—消化系统]